Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesotheliomaRiki Okita(National Sanyo Hospital), Keisuke Aoe(National Sanyo Hospital)Scientific ReportsJuly 10, 202410.1038/s41598-024-66189-5Cited by 3SaveCiteExport RISWatch citationsRelated PapersPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial|The Lancet|2019|3.3kContrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells|PLoS ONE|2015|37Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells|Oncology Reports|2015|22